{"slug":"gene-nucleic-acid","as_of":"2026-10-22","verified_at":"2026-10-22","languages":{"zh":{"title":"台灣核酸與基因治療公司總表","summary":[{"text":"截至2026年10月22日，本表收錄3家台灣公司的核酸或基因治療管線。","source_urls":["https://onenessbio.com/pipeline/development-progress/sns812/","https://www.bionettx.com/development-pipeline/","https://mopsov.twse.com.tw/nas/STR/649620251216M001.pdf"]},{"text":"合一SNS812已完成第2期，訊聯智藥的siRNA疤痕預防計畫與科懋EX-054基因治療均列為臨床前。","source_urls":["https://onenessbio.com/pipeline/development-progress/sns812/","https://www.bionettx.com/development-pipeline/","https://mopsov.twse.com.tw/nas/STR/649620251216M001.pdf"]}],"undisclosed":"本表是核對來源後的公司與所選管線名單，並非完整產業清冊。階段依逐列來源日期描述，未公開的品名、適應症與事件日期不填補。"},"en":{"title":"Taiwan Nucleic Acid and Gene Therapy Companies","summary":[{"text":"As of October 22, 2026, this table includes nucleic acid or gene-therapy programs at 3 Taiwan companies.","source_urls":["https://onenessbio.com/pipeline/development-progress/sns812/","https://www.bionettx.com/development-pipeline/","https://mopsov.twse.com.tw/nas/STR/649620251216M001.pdf"]},{"text":"SNS812 has completed Phase 2, while the BIONET siRNA scar-prevention program and Excelsior EX-054 gene therapy are listed as preclinical.","source_urls":["https://onenessbio.com/pipeline/development-progress/sns812/","https://www.bionettx.com/development-pipeline/","https://mopsov.twse.com.tw/nas/STR/649620251216M001.pdf"]}],"undisclosed":"This is a source-verified selection rather than an industry census. Stages retain their individual source dates; undisclosed names, indications and event dates are not filled in."}},"companies":[{"company":"合一","company_en":"Oneness Biotech","ticker":"4743","product":"SNS812（siRNA）","product_en":"SNS812 (siRNA)","indication":"冠狀病毒感染","indication_en":"Coronavirus infection","stage":"第2期已完成並取得最終臨床研究報告","stage_en":"Phase 2 complete; final clinical study report obtained","as_of":"2026-10-22","source":"https://onenessbio.com/pipeline/development-progress/sns812/","quote":"完成二期臨床試驗，並取得最終臨床研究報告","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"合一生技股份有限公司","catalyst":null,"date_basis":"無日期現行公司開發頁；as_of為本次查閱日，並非試驗完成日期。"},{"company":"訊聯智藥","company_en":"BIONET Therapeutics","ticker":"7808","product":"siRNA疤痕預防計畫（個別藥物代號查無）","product_en":"siRNA scar-prevention program (individual drug code undisclosed)","indication":"疤痕預防","indication_en":"Scar prevention","stage":"臨床前","stage_en":"Preclinical","as_of":"2026-10-22","source":"https://www.bionettx.com/development-pipeline/","quote":"siRNA","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R","company_quote":"訊聯細胞智藥股份有限公司","catalyst":null,"date_basis":"無日期現行管線表；as_of為查閱日。"},{"company":"科懋","company_en":"Excelsior Biopharma","ticker":"6496","product":"EX-054（基因治療）","product_en":"EX-054 (gene therapy)","indication":"有機酸血症","indication_en":"Organic acidemia","stage":"臨床前","stage_en":"Preclinical","as_of":"2025-12-16","source":"https://mopsov.twse.com.tw/nas/STR/649620251216M001.pdf","quote":"EX-054 有機酸血症(基因治療)","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"科懋生物科技股份有限公司","catalyst":null,"source_page":62,"date_basis":"封面明示民國114年12月16日；第62頁EX-054箭頭停在Preclinical欄，已視覺核對，未宣稱有更晚階段更新。"}],"scope":{"not_exhaustive":true,"coverage":"Verified selection from the same read-only company-profile and pipeline inputs used in 0b04, because deploy/engine/src/data does not contain the original company profiles. One program selected per company.","stage_basis":"Stages reflect the cited source and its stated date. An undated live page uses the access date; source review does not make an old status a newly reported event.","count_basis":"Company rows, not independent assets or an industry-wide census. Parent-group, therapeutic-vaccine and planned regulatory-pathway roles are identified in each row."}}